Amgen (AMGN) to Boost Inflammation Pipeline With Rodeo Buyout
Amgen Inc. AMGN announced an agreement to acquire Seattle, WA-based privately held biopharmaceutical company, Rodeo Therapeutics Corporation, which is engaged in developing small-molecule therapies designed to promote regeneration and repair of multiple tissues.
The deal will boost Amgen’s inflammation portfolio and its efforts to develop first-in-class therapeutics for patients.
Per the deal, Amgen will acquire all outstanding shares of Rodeo for an upfront payment of $55 million, as well as future contingent milestone payments potentially worth up to $666 million in cash. Rodeo's lead 15-prostaglandin dehydrogenase (15-PGDH) modulators have demonstrated encouraging data in preclinical studies and have the potential to be used in across a range of therapeutic applications including inflammatory disease indications.
The transaction has been approved by the shareholders and the board of directors of Rodeo.
Shares of Amgen have rallied 8.6% so far this year against the industry’s decrease of 3.8%.
We note that Amgen has an encouraging history of driving growth and boosting its pipeline through deals and acquisitions. Key acquisitions in the past added Kyprolis and Blincyto to its portfolio, which have become important growth drivers for the company.
Meanwhile, in November 2019, Amgen acquired global commercial rights to Celgene’s [now part of Bristol-Myers BMY] blockbuster psoriasis drug, Otezla. The acquisition significantly strengthened its inflammation portfolio, which has also become an important growth driver.
This apart, in March 2021, Amgen announced an agreement to acquire small biotech, Five Prime Therapeutics, for $38 per share or a total equity value of approximately $1.9 billion to strengthen its oncology portfolio. The acquisition will add the latter’s lead pipeline candidate, bemarituzumab, a first-in-class, phase III ready, anti-FGFR2b antibody, to its portfolio. The transaction is expected to close by the end of the second quarter of 2021.
Zacks Rank & Stocks to Consider
Amgen currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector include Nabriva Therapeutics AG NBRV and Repligen Corporation RGEN, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Nabriva Therapeutics’ loss per share estimates have narrowed 45.8% for 2021 and 50.9% for 2022, over the past 60 days.
Repligen’s earnings estimates have been revised 15.1% upward for 2021 and 9.8% upward for 2022 over the past 60 days.
5G Revolution: 3 Stocks to Make Your Move
With super high data speed, it will make current cell phones obsolete and unlock the full potential of big data, cloud computing, and artificial intelligence. In the next few years this industry is predicted to create 22 million jobs and a stunning $12.3 trillion in revenue.
Today you have an historic chance to pursue almost unimaginable gains like Microsoft, Netflix, and Apple in their early phases. Zacks has released a Special Report that reveals our . . .
Smartest stock for 5G telecom
Safest investment in 5G hardware
Single best 5G buy of all!
Download now. Today the report is FREE >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report
Repligen Corporation (RGEN) : Free Stock Analysis Report
Nabriva Therapeutics AG (NBRV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
